| Assessment Status | Rapid Review Complete |
| HTA ID | - |
| Drug | Olaparib |
| Brand | Lynparza® |
| Indication | For the treatment of adult patients with germline BRCA1/2 mutations, who have HER2-negative locally advanced or metastatic breast cancer. Patients should have previously been treated with an anthracycline and a taxane in the (neo)adjuvant or metastatic setting unless patients were not suitable for these treatments. |
| Assessment Process | |
| Rapid review commissioned | 29/03/2019 |
| Rapid review completed | 10/04/2019 |
| Rapid review outcome | A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of olaparib compared with the current standard of care. |
The company has not submitted a HTA dossier to the NCPE therefore the cost effectiveness of the technology could not be proven.
